Skip to main content

Human 4-1BB/TNFRSF9/CD137 ELISA Kit (Colorimetric), Novus Biologicals

Bio-Techne includes Novus Biologicals | Catalog # NBP1-91278

Catalog #
Size / Price

Key Product Details

Sample Type & Volume Required Per Well

Cell culture supernatant, serum (50 uL)


0.2 ng/mL

Assay Range

0.78 - 50 ng/mL

Product Specifications

Assay Type

Sandwich ELISA

Kit Type

ELISA Kit (Colorimetric)




The interference of circulating factors of the immune systemwas evaluated by spiking these proteins at physiologically relevant concentrations into a human 4-1BB/TNFRSF9/CD137 positive serum. There was no crossreactivity detected.


The human sCD137 ELISA is an enzyme-linked immunosorbent assay for the quantitative detection of human sCD137.


Intra-Assay Precision (Precision within an assay) CV% < 7.10%

Inter-Assay Precision (Precision between assays) CV% < 9.90%

Recovery for Human 4-1BB/TNFRSF9/CD137 ELISA Kit (Colorimetric)



Scientific Data Images for Human 4-1BB/TNFRSF9/CD137 ELISA Kit (Colorimetric)

4-1BB/TNFRSF9/CD137 ELISA Kit [NBP1-91278] - Data for Human sCD137 (s4-1BB) Platinum ELISA

Kit Contents for Human 4-1BB/TNFRSF9/CD137 ELISA Kit (Colorimetric)

  • Adhesive Films
  • Aluminium pouch(es) with a Microwell Plate coated with monoclonal antibody to human sCD137
  • Assay Buffer Concentrate 20x (PBS with 1% Tween 20 and 10% BSA)
  • Biotin-Conjugate anti-human sCD137 polyclonal antibody
  • Human sCD137 Standard lyophilized, 100 ng/ml upon reconstitution
  • Sample Diluent
  • Stop Solution (1M Phosphoric acid)
  • Streptavidin-HRP
  • Substrate Solution (tetramethyl-benzidine)
  • Wash Buffer Concentrate 20x (PBS with 1% Tween 20)

Preparation and Storage


The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Storage of components varies. See protocol for specific instructions.

Background: 4-1BB/TNFRSF9/CD137

4-1BB, also called CD137 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9), is a type I surface glycoprotein expressed on activated T cell and natural killer (NK) cells (1,2). Human 4-1BB protein is 255 amino acids (aa) in length with a theoretical molecular weight of 28 kDa. It contains an extracellular domain, a helical transmembrane domain, and a cytoplasmic/intracellular domain (3). 4-1BB/TNFRSF9/CD137 is a costimulatory receptor that binds the ligand 4-1BBL/CD137L which is primarily expressed on antigen presenting cells (APCs) such as dendritic cells (DCs), macrophages, and B cells (1,2,4,5). The 4-1BB receptor-ligand interaction results in recruitment of TNFR-associated factor (TRAF) family adaptor proteins to 4-1BB's cytoplasmic domain (1,2,4,5). TRAF1, TRAF2, and TRAF3 are found in various homodimer and/or heterodimer configurations. Their recruitment to 4-1BB/CD137 initiates signalosome formation as well as activation of the nuclear factor-kappa B (NF-kappaB) and mitogen-activated protein kinase (MAPK) signaling cascade (1,4,5). 4-1BB/TNFRSF9/CD137 stimulation leads to increased cellular cytotoxic activity and pro-inflammatory cytokine production (1,2,4). Given its role in immune cell activation, 4-1BB has become a promising target for cancer immunotherapy (1,2,4). Current approaches to target 4-1BB include agonistic monoclonal and bispecific anti-4-1BB antibodies and well as utilizing the cytoplasmic domain of 4-1BB in generating chimeric antigen receptors (CARs) (1,2,4). 4-1BB agonists in clinical trials include Urelumab and Utolimumab. Utolimumab also has ligand blocking properties whereas Urelumab does not (1,2,4). Anti-4-1BB monoclonal antibodies are being tested as monotherapy as well as combination therapy with either other immunostimulatory monoclonal antibodies or with checkpoint blockade antibodies like anti-PD-1 (1,2,4).


1. Etxeberria, I., Glez-Vaz, J., Teijeira, A., & Melero, I. (2020). New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis. ESMO open, 4(Suppl 3), e000733.

2. Chester, C., Sanmamed, M. F., Wang, J., & Melero, I. (2018). Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood, 131(1), 49-57.

3. Uniport (Q07011)

4. Chester, C., Ambulkar, S., & Kohrt, H. E. (2016). 4-1BB agonism: adding the accelerator to cancer immunotherapy. Cancer Immunology, Immunotherapy: CII, 65(10), 1243-1248.

5. Zapata, J. M., Perez-Chacon, G., Carr-Baena, P., Martinez-Forero, I., Azpilikueta, A., Otano, I., & Melero, I. (2018). CD137 (4-1BB) signalosome: complexity is a matter of TRAFs. Frontiers in Immunology, 9, 2618.

Alternate Names


Gene Symbol


Additional 4-1BB/TNFRSF9/CD137 Products

Product Documents for Human 4-1BB/TNFRSF9/CD137 ELISA Kit (Colorimetric)

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for Human 4-1BB/TNFRSF9/CD137 ELISA Kit (Colorimetric)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. ELISA Kits are guaranteed for 6 months from date of receipt.